A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients With Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers With Hepatic Metastases.
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs TKM PLK1 (Primary)
- Indications Breast cancer; Colorectal cancer; Liver cancer; Liver metastases; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 25 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 25 Jun 2012 Additional lead trial investigator (Thomas S Uldrick) identified and actual patients number (1) added as reported by ClinicalTrials.gov.
- 27 Mar 2012 Status changed from recruiting to discontinued according to a Tekmira media release. Proof-of-concept of LNP technology was established based on interim results from Alnylam's programmes that utilise Tekmira's LNP technology.